Orris

Give me answers of second sessional questions

Reading File
Reading File
Running Command

cd /home/daytona/workspace/attachments/cb66ceec-751d-4ddf-be20-53a09141a8b7 && python3 -c " import pdfplumber with pdfplumber.open('medicine questions papers.pdf') as pdf: for i, page in enumerate(pdf.pages): print(f'=== PAGE {i+1} ===') text = page.extract_text() if text: print(text) print() "

Running Command

cd /home/daytona/workspace/attachments/cb66ceec-751d-4ddf-be20-53a09141a8b7 && python3 -c " from pypdf import PdfReader import base64, os reader = PdfReader('medicine questions papers.pdf') print(f'Pages: {len(reader.pages)}') # Try to extract images from pages for i, page in enumerate(reader.pages): print(f'Page {i+1} images: {len(page.images)}') for j, img in enumerate(page.images): fname = f'/home/daytona/workspace/attachments/page{i+1}_img{j+1}.{img.name.split(\".\")[-1] if \".\" in img.name else \"png\"}' with open(fname, 'wb') as f: f.write(img.data) print(f' Saved: {fname}') "

analyse_media
analyse_media
analyse_media
Running Command

python3 -c " import pytesseract from PIL import Image for i in range(1, 4): img = Image.open(f'/home/daytona/workspace/attachments/page{i}_img1.jpg') text = pytesseract.image_to_string(img) print(f'=== PAGE {i} ===') print(text) print() "

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here are detailed answers for all 10 questions from your IInd Sessional Examination (MBBS 3rd Prof. Part II - Medicine):

Sri Aurobindo Medical College - IInd Sessional Answers

Q1. Define Diabetes Mellitus. What are the different types of diabetes? (10 marks)

Definition

Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It leads to long-term damage, dysfunction, and failure of various organs - especially the eyes, kidneys, nerves, heart, and blood vessels.
ADA Diagnostic Criteria (any one of the following):
  • Fasting plasma glucose ≥ 126 mg/dL
  • 2-hour plasma glucose ≥ 200 mg/dL during OGTT (75 g glucose)
  • HbA1c ≥ 6.5%
  • Random plasma glucose ≥ 200 mg/dL + symptoms of hyperglycemia

Types of Diabetes Mellitus (ADA Classification)

1. Type 1 Diabetes Mellitus (T1DM)
  • Autoimmune destruction of beta cells → absolute insulin deficiency
  • Usually presents in childhood/adolescence (but can occur at any age)
  • Positive autoantibodies: anti-GAD, anti-islet cell (ICA), anti-insulin (IAA)
  • Prone to diabetic ketoacidosis (DKA)
  • Treatment: Insulin is mandatory
2. Type 2 Diabetes Mellitus (T2DM)
  • Combination of insulin resistance + relative insulin deficiency
  • Most common type (~90-95% of all DM)
  • Associated with obesity, sedentary lifestyle, family history
  • Insidious onset; often diagnosed incidentally
  • Treatment: lifestyle modification, oral hypoglycemics, insulin if needed
3. Gestational Diabetes Mellitus (GDM)
  • Glucose intolerance first recognized during pregnancy (any trimester)
  • Diagnosed by 75g OGTT at 24-28 weeks
  • Risk: macrosomia, preeclampsia, neonatal hypoglycemia
  • Usually resolves postpartum but increases risk of T2DM later
4. Other Specific Types
  • MODY (Maturity Onset Diabetes of the Young): Monogenic; autosomal dominant; multiple types (MODY 1-6)
  • Secondary DM: Due to pancreatitis, hemochromatosis, Cushing's syndrome, acromegaly, glucagonoma, drugs (steroids, thiazides)
  • Neonatal DM: Before 6 months of age; usually monogenic
  • Latent Autoimmune Diabetes in Adults (LADA): Slow autoimmune destruction; adult age, initially resembles T2DM

Prediabetes

  • Impaired Fasting Glucose (IFG): FPG 100-125 mg/dL
  • Impaired Glucose Tolerance (IGT): 2-hr PG 140-199 mg/dL during OGTT

Q2. Duke's Criteria for Diagnosis of Infective Endocarditis (10 marks)

Infective endocarditis (IE) is an infection of the endocardial surface of the heart, usually involving cardiac valves.

Modified Duke Criteria

MAJOR CRITERIA
1. Positive Blood Cultures:
  • Typical microorganism (Strep viridans, Strep bovis, HACEK group, Staph aureus, community-acquired Enterococcus) from 2 separate blood cultures
  • OR persistently positive blood cultures (≥2 cultures drawn >12 hrs apart; or all 3 of ≥4 cultures with first and last drawn ≥1 hr apart)
  • Single positive blood culture for Coxiella burnetii, or IgG antibody titer >1:800
2. Evidence of Endocardial Involvement:
  • Positive echocardiogram (TTE/TEE): oscillating intracardiac mass on valve/supporting structures, abscess, new partial dehiscence of prosthetic valve
  • New valvular regurgitation (change in pre-existing murmur is NOT sufficient)
MINOR CRITERIA
  1. Predisposing heart condition (MVP, rheumatic heart disease, prosthetic valve, IVDU)
  2. Fever ≥ 38°C (100.4°F)
  3. Vascular phenomena: arterial emboli, septic pulmonary infarcts, Janeway lesions, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhage
  4. Immunologic phenomena: Osler nodes, Roth spots, Glomerulonephritis, positive Rheumatoid factor
  5. Microbiological evidence: positive blood culture not meeting major criterion; or serological evidence of active infection
  6. Echocardiographic evidence not meeting major criterion

Classification

CategoryCriteria
Definite IE2 Major, OR 1 Major + 3 Minor, OR 5 Minor
Possible IE1 Major + 1 Minor, OR 3 Minor
RejectedFirm alternative diagnosis, OR resolution of symptoms ≤4 days of antibiotics, OR no pathologic evidence at surgery/autopsy

Classic Clinical Features (memory aid - FROM JANE)

  • Fever
  • Roth spots (flame-shaped retinal hemorrhages)
  • Osler nodes (painful nodules on finger/toe pads)
  • Murmur (new/changing)
  • Janeway lesions (non-tender hemorrhagic macules on palms/soles)
  • Anemia
  • Nail-bed hemorrhages (splinter hemorrhages)
  • Emboli

Q3. Diagnosis and Management of Rheumatoid Arthritis (10 marks)

Definition

Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic symmetric inflammatory polyarthritis, primarily affecting synovial joints.

Diagnosis

ACR/EULAR 2010 Classification Criteria (Score ≥6 = definite RA):
ParameterScore
Joint involvement: 1 large joint0
2-10 large joints1
1-3 small joints2
4-10 small joints3
>10 joints (at least 1 small)5
Serology: Negative RF and anti-CCP0
Low positive RF or anti-CCP2
High positive RF or anti-CCP3
Acute phase reactants: Normal CRP and ESR0
Abnormal CRP or ESR1
Duration: <6 weeks0
≥6 weeks1
Investigations:
  • RF (Rheumatoid Factor): positive in 70-80%
  • Anti-CCP antibody (more specific ~95%)
  • ESR and CRP (elevated)
  • FBC: normocytic normochromic anemia, thrombocytosis
  • X-ray: periarticular osteopenia, joint space narrowing, marginal erosions, subluxation
  • MRI/Ultrasound: synovitis, erosions (earlier detection)
Clinical Features:
  • Morning stiffness >1 hour
  • Symmetric small joint involvement (MCP, PIP, wrists - spares DIP)
  • Deformities: Ulnar deviation, swan neck, boutonniere, Z-thumb
  • Extra-articular: rheumatoid nodules, Felty syndrome, vasculitis, pleural effusion, pericarditis, scleritis, amyloidosis

Management

Non-pharmacological:
  • Patient education, physiotherapy, occupational therapy
  • Joint protection, splinting, exercise
Pharmacological:
Step 1 - Symptomatic relief:
  • NSAIDs (e.g., diclofenac, naproxen) - for pain and stiffness
  • Short-course corticosteroids (bridge therapy while DMARDs take effect)
Step 2 - DMARDs (Disease-Modifying Anti-Rheumatic Drugs):
  • Methotrexate (first-line DMARD) - 7.5-25 mg/week; monitor LFTs, FBC
  • Hydroxychloroquine - less aggressive disease
  • Sulfasalazine
  • Leflunomide
Step 3 - Biological DMARDs (if inadequate response):
  • Anti-TNF agents: Etanercept, Infliximab, Adalimumab
  • Anti-IL-6: Tocilizumab
  • Anti-CD20: Rituximab
  • CTLA-4Ig: Abatacept
Step 4 - Targeted synthetic DMARDs:
  • JAK inhibitors: Tofacitinib, Baricitinib
Surgical: Synovectomy, joint replacement (severe irreversible damage)
Treatment Target: Low disease activity or remission (DAS28 score <2.6)

Q4. Clinical Features, Complications and Treatment of Systemic Lupus Erythematosus (SLE) (10 marks)

Definition

SLE is a chronic, multisystem autoimmune disease characterized by production of autoantibodies against nuclear antigens, immune complex deposition, and widespread inflammation.

Clinical Features (mnemonic: DOPAMINE RASH)

  • Discoid rash (chronic scarring)
  • Oral ulcers (painless)
  • Photosensitivity
  • Arthritis (non-erosive, symmetric)
  • Malar rash ("butterfly rash" - over cheeks/nose, spares nasolabial folds)
  • Immunologic disorders (anti-dsDNA, anti-Sm, antiphospholipid Ab)
  • Neurological (seizures, psychosis)
  • Erythrocyte involvement (hemolytic anemia)
  • Renal (lupus nephritis)
  • ANA positive
  • Serositis (pleuritis, pericarditis)
  • Hematologic (leukopenia, lymphopenia, thrombocytopenia)
ACR/EULAR 2019 Classification Criteria: Mandatory criterion: ANA positive (≥1:80); additional domains scored.
Autoantibodies:
  • ANA - highly sensitive (~95-99%), not specific
  • Anti-dsDNA - specific, correlates with disease activity and nephritis
  • Anti-Sm - most specific (30% sensitivity)
  • Anti-Ro/La - neonatal lupus, Sjogren overlap
  • Antiphospholipid antibodies - thrombosis, pregnancy loss

Complications

Renal (Lupus Nephritis - WHO Classes I-VI):
  • Class III/IV (proliferative) most severe
  • Presents with hematuria, proteinuria, hypertension, AKI/CKD
Cardiovascular:
  • Libman-Sacks endocarditis (sterile verrucous vegetations on mitral valve)
  • Premature atherosclerosis, pericarditis, myocarditis
Neuropsychiatric SLE (NPSLE):
  • Seizures, psychosis, cerebrovascular disease, peripheral neuropathy
Hematological:
  • Evans syndrome (AIHA + thrombocytopenia)
  • Increased infection risk
Antiphospholipid Syndrome:
  • Recurrent thrombosis, pregnancy loss, livedo reticularis

Treatment

Mild disease (rash, arthritis):
  • Hydroxychloroquine (200-400 mg/day) - backbone of SLE treatment; reduces flares and mortality
  • NSAIDs for joint/serositis symptoms
  • Sunscreen, avoid sun exposure
Moderate-severe disease:
  • Corticosteroids: prednisolone 0.5-1 mg/kg/day
  • Immunosuppressants: Azathioprine, Mycophenolate mofetil (MMF), Methotrexate
Severe/life-threatening (nephritis, CNS, cytopenias):
  • High-dose IV methylprednisolone (pulse therapy)
  • Cyclophosphamide (NIH protocol or Euro-Lupus low-dose)
  • MMF preferred for induction and maintenance in lupus nephritis
Biologics:
  • Belimumab (anti-BLyS) - reduces flares
  • Voclosporin/Anifrolumab (newer approvals)
Antiphospholipid syndrome: Long-term anticoagulation (warfarin)

Q5. Clinical Features, Diagnosis and Treatment of Rheumatic Heart Disease (10 marks)

Background

Rheumatic Heart Disease (RHD) is the cardiac sequela of Acute Rheumatic Fever (ARF), caused by Group A beta-hemolytic Streptococcus (Strep pyogenes) pharyngitis. The mechanism is molecular mimicry - streptococcal M protein antigens cross-react with cardiac tissue.

Acute Rheumatic Fever - Jones Criteria (2015 Revision)

Major Criteria:
  • Carditis (clinical or subclinical/echocardiographic)
  • Polyarthritis (migratory, large joints - in high-risk populations; monoarthritis also counts)
  • Chorea (Sydenham's chorea - purposeless involuntary movements)
  • Erythema marginatum (pink-red rings with central clearing on trunk)
  • Subcutaneous nodules (firm, painless, over bony prominences)
Minor Criteria:
  • Fever (≥38.5°C)
  • Elevated acute phase reactants (ESR ≥60 mm/hr; CRP ≥3 mg/dL)
  • Prolonged PR interval on ECG
Prerequisite: Evidence of preceding Group A Strep infection (positive throat culture/rapid test OR elevated/rising ASO titer)
Diagnosis = 2 Major OR 1 Major + 2 Minor + preceding strep infection

Clinical Features of RHD (Chronic)

Mitral Stenosis (most common - 40% pure MS, 40% MS+MR):
  • Opening snap + mid-diastolic rumble at apex
  • Malar flush, atrial fibrillation
  • Pulmonary hypertension, hemoptysis, systemic emboli
Mitral Regurgitation:
  • Pansystolic murmur radiating to axilla
  • Volume overload, LV dilatation
Aortic Stenosis / Regurgitation: Less common in RHD
Other: Mitral valve area <1 cm² = severe MS (normal 4-6 cm²)

Investigations

  • ECG: P-mitrale (bifid P waves), AF, RVH, LVH
  • CXR: Cardiomegaly, pulmonary congestion, Kerley B lines
  • Echocardiography: Gold standard - assess valve morphology, gradients, area, ventricular function
  • Throat culture / ASO titer

Treatment

Primary Prevention: Treat strep pharyngitis with Penicillin V (10 days) or single dose Benzathine Penicillin IM 1.2 million units
Secondary Prevention (long-term):
  • Benzathine Penicillin G 1.2 MU IM every 3-4 weeks
  • Duration: 10 years or until age 40 (whichever longer); lifelong if carditis with residual disease
Medical management of MS:
  • Beta-blockers/digoxin/verapamil for rate control in AF
  • Diuretics for pulmonary congestion
  • Anticoagulation for AF or prior emboli (warfarin)
Interventional:
  • Balloon mitral valvuloplasty (PTMC): Wilkins score ≤8, no MR, no thrombus
  • Mitral valve repair or replacement for severe refractory cases
Infective Endocarditis prophylaxis: Amoxicillin before dental procedures

Q6. Difference Between Limited and Diffuse Systemic Sclerosis (10 marks)

Systemic Sclerosis (SSc/Scleroderma) is a multisystem connective tissue disease characterized by fibrosis of skin and internal organs, vasculopathy, and autoimmunity.

Comparison Table

FeatureLimited Cutaneous SSc (lcSSc)Diffuse Cutaneous SSc (dcSSc)
Skin involvementDistal to elbows/knees + faceDiffuse - proximal limbs, trunk, face
OnsetInsidiousRapid
Raynaud's phenomenonYears before skin changesClose to skin changes
Internal organ involvementLate, less severeEarly, severe
Pulmonary hypertensionCommon (isolated PAH)Less common
Pulmonary fibrosisLess commonMore common
Renal crisisRareMore common
GI involvementLess severeMore severe
AntibodiesAnti-centromere antibody (ACA) ~70%Anti-Scl-70 (anti-topoisomerase-I) ~30%
PrognosisBetter (slower progression)Worse (rapid progression)
Old termCREST syndrome-
Cardiac involvementRareMore common

CREST Syndrome (Limited SSc):

  • Calcinosis (calcium deposits in skin)
  • Raynaud's phenomenon
  • Esophageal dysmotility
  • Sclerodactyly (thickened, tight finger skin)
  • Telangiectasia

Pathophysiology

Three hallmarks: (1) Vasculopathy - endothelial injury, Raynaud's phenomenon; (2) Autoimmunity - T-cell activation, autoantibody production; (3) Fibrosis - TGF-beta driven excessive collagen deposition by fibroblasts.

Common Features to Both

  • Raynaud's phenomenon (nearly universal)
  • Skin thickening (sclerodactyly)
  • GI: Esophageal hypomotility, GERD, malabsorption
  • Interstitial lung disease

Treatment

  • No disease-modifying agent proven definitively effective
  • Raynaud's: Calcium channel blockers (nifedipine), endothelin receptor antagonists (bosentan for digital ulcers)
  • PAH: Sildenafil, bosentan, epoprostenol
  • Pulmonary fibrosis: Nintedanib, mycophenolate mofetil
  • Renal crisis: ACE inhibitors (captopril) - do NOT withhold even in advanced CKD
  • GERD: Proton pump inhibitors
  • Skin fibrosis: Methotrexate, mycophenolate

Q7. Young Onset Diabetes Mellitus (10 marks)

Definition

Young Onset Diabetes Mellitus (YODM) refers to diabetes diagnosed at age <25-40 years (cut-off varies by guideline). In Western literature it is typically <40 years; in Asian/Indian populations, it is often defined as <25 years due to earlier onset.

Types

1. Type 1 DM (T1DM)
  • Most common in children/adolescents
  • Autoimmune - GAD, IA-2, ICA, ZnT8 antibodies
  • Absolute insulin deficiency, DKA-prone
  • Thin body habitus
  • HLA-DR3, HLA-DR4 associations
2. Type 2 DM in Young
  • Rapidly increasing due to obesity epidemic
  • Insulin resistance + relative insulin deficiency
  • Strong family history, metabolic syndrome features
  • Often asymptomatic at diagnosis
  • More aggressive than adult-onset T2DM
3. MODY (Maturity Onset Diabetes of the Young)
  • Monogenic diabetes; autosomal dominant
  • Age <25 years, non-obese, 3+ generations affected
  • Negative autoantibodies, no insulin requirement initially
  • Types:
    • MODY 1 (HNF-4α): responds to sulfonylureas
    • MODY 2 (GCK): mild stable hyperglycemia, often treatment not needed
    • MODY 3 (HNF-1α): most common; sulfonylurea-sensitive
    • MODY 5 (HNF-1β): renal cysts + diabetes
4. Neonatal DM: < 6 months; KCNJ11, ABCC8 mutations; may be transient or permanent
5. LADA (Latent Autoimmune Diabetes in Adults): Slow autoimmune; initially non-insulin requiring; positive GADA
6. Secondary causes in young:
  • Pancreatogenic (tropical/chronic pancreatitis - common in India)
  • Cystic fibrosis-related DM
  • Drug-induced (steroids, antiretrovirals)

Features of YODM that differ from older-onset T2DM:

  • More aggressive beta-cell decline
  • Earlier complications (micro and macrovascular)
  • Higher cardiovascular risk at younger age
  • Fertility and pregnancy complications in women
  • Psychological impact (adolescent with chronic disease)

Management Principles

  • Type 1: Intensive insulin therapy (basal-bolus regimen), CSII (pump), CGM
  • Type 2 in young: Lifestyle modification first; metformin; consider SGLT2i/GLP-1RA
  • MODY: Genetic testing; targeted therapy (sulfonylureas for MODY 1/3)
  • Multidisciplinary: Endocrinologist, ophthalmologist, nephrologist, dietitian, psychologist
  • Screening for complications from diagnosis
  • Contraception counseling, preconception planning for females

Q8. Clinical Features, Diagnosis and Treatment of Gout (10 marks)

Definition

Gout is a crystal deposition disease caused by monosodium urate (MSU) crystal deposition in joints and soft tissues due to hyperuricemia (serum uric acid >6.8 mg/dL in men; >6.0 mg/dL in women).

Pathophysiology

Hyperuricemia → MSU crystal deposition in joints → crystal phagocytosis by neutrophils → IL-1β, TNF-α release → acute inflammatory arthritis (gouty attack)
Causes of Hyperuricemia:
  • Underexcretion (90%): Renal disease, diuretics (thiazides, loop), low-dose aspirin, cyclosporin, alcohol
  • Overproduction (10%): High purine diet (red meat, shellfish, organ meats), alcohol, myeloproliferative disorders, hemolytic anemia, Lesch-Nyhan syndrome (HPRT deficiency)

Clinical Stages

1. Asymptomatic hyperuricemia: No symptoms; may deposit crystals
2. Acute Gouty Arthritis:
  • Sudden severe pain, swelling, warmth, erythema (may desquamate)
  • Podagra = 1st MTP joint (great toe) - most classic site (75% of first attacks)
  • Other joints: ankle, knee, wrist, elbow
  • May be triggered by: alcohol, red meat, trauma, surgery, dehydration, starting allopurinol
  • Self-limiting: resolves in days to weeks
  • Fever, leukocytosis may occur
3. Intercritical Gout: Asymptomatic periods between attacks
4. Chronic Tophaceous Gout:
  • Tophi: chalky white MSU deposits in pinnae of ear, olecranon, Achilles tendon, finger pads
  • Chronic polyarthritis, joint deformity
  • Renal complications: urate nephropathy, uric acid nephrolithiasis

Diagnosis

Gold Standard: Synovial fluid aspiration - polarized light microscopy showing needle-shaped, negatively birefringent MSU crystals (yellow when parallel to polarizer)
Investigations:
  • Serum uric acid (may be normal during acute attack)
  • FBC: leukocytosis during attack
  • ESR, CRP: elevated
  • X-ray: "rat-bite" / "punched-out" erosions with overhanging edges ("Martel's sign"), tophi, joint space preserved until late
  • Ultrasound: "double contour sign" (urate on cartilage surface)
  • DECT (Dual Energy CT): excellent for detecting tophi

Treatment

Acute Attack:
  1. NSAIDs (first-line): Indomethacin 50 mg TID or Naproxen - most effective if started early
  2. Colchicine: 1.2 mg then 0.6 mg 1 hour later; effective within 36 hours; diarrhea common; avoid in renal failure
  3. Corticosteroids: IM/intra-articular/oral prednisolone; for patients who cannot take NSAIDs/colchicine
Urate-Lowering Therapy (ULT) - start after acute attack resolves (wait 2-4 weeks):
Indications: ≥2 attacks/year, tophi, chronic tophaceous gout, uric acid nephrolithiasis, serum UA >9 mg/dL
  • Allopurinol (first-line XO inhibitor): start low (100 mg/day), titrate to target UA <6 mg/dL; risk of DRESS/SJS (screen HLA-B*5801 in Asian patients)
  • Febuxostat: alternative XO inhibitor (more potent); cardiovascular risk concerns
  • Probenecid: uricosuric agent; avoid if nephrolithiasis or renal impairment
  • Pegloticase: IV recombinant uricase for refractory tophaceous gout
Prophylaxis during ULT initiation: Colchicine 0.6 mg daily for 6 months to prevent mobilization flares
Lifestyle: Reduce red meat, shellfish, alcohol (especially beer/spirits); increase water intake; avoid diuretics where possible; weight loss

Q9. Clinical Manifestations of Collagen Vascular Diseases (10 marks)

Collagen vascular diseases (CVDs), also called connective tissue diseases (CTDs), are a group of autoimmune disorders affecting connective tissue throughout the body. Key diseases include:

1. Systemic Lupus Erythematosus (SLE)

  • Malar rash, discoid rash, photosensitivity
  • Non-erosive arthritis, oral ulcers
  • Serositis (pleuritis, pericarditis)
  • Renal involvement (lupus nephritis)
  • Neuropsychiatric: seizures, psychosis
  • Hematologic: hemolytic anemia, leukopenia, thrombocytopenia
  • ANA, anti-dsDNA, anti-Sm antibodies

2. Rheumatoid Arthritis (RA)

  • Symmetric small joint inflammatory arthritis (MCP, PIP, wrists)
  • Morning stiffness >1 hour
  • Rheumatoid nodules (extensor surfaces)
  • Extra-articular: pleural effusion, pericarditis, scleritis, vasculitis, Felty syndrome
  • RF, anti-CCP antibodies

3. Systemic Sclerosis (Scleroderma)

  • Raynaud's phenomenon (often first manifestation)
  • Skin thickening (sclerodactyly, truncal in diffuse)
  • CREST features in limited form
  • Pulmonary fibrosis, pulmonary arterial hypertension
  • Renal crisis (malignant hypertension)
  • GI dysmotility
  • Anti-centromere (lcSSc), anti-Scl-70 (dcSSc)

4. Polymyositis (PM) / Dermatomyositis (DM)

  • PM: Proximal muscle weakness (shoulder/hip girdle), elevated CK/aldolase, inflammatory on biopsy
  • DM: PM + skin features:
    • Heliotrope rash (violaceous rash around eyes)
    • Gottron's papules (scaly papules over MCP/PIP knuckles)
    • V-sign, Shawl sign
    • "Mechanic's hands" (Anti-Jo-1 positive - antisynthetase syndrome)
  • DM: associated with malignancy (30% in older patients)
  • Anti-Jo1, anti-Mi2, anti-MDA5 antibodies

5. Sjogren's Syndrome

  • Primary: Sicca complex (keratoconjunctivitis sicca + xerostomia)
  • Dry eyes (Schirmer's test <5 mm), dry mouth, parotid enlargement
  • Secondary: Associated with RA, SLE, SSc
  • Systemic: arthralgia, interstitial nephritis, peripheral neuropathy, lymphoma (20x risk)
  • Anti-Ro (SSA), Anti-La (SSB) antibodies

6. Mixed Connective Tissue Disease (MCTD)

  • Overlap features of SLE, SSc, PM
  • High-titer anti-U1 RNP antibodies
  • Raynaud's, swollen hands, myositis, pulmonary hypertension

7. Antiphospholipid Syndrome (APS)

  • Arterial and/or venous thrombosis
  • Recurrent pregnancy loss (2nd trimester fetal loss)
  • Livedo reticularis, thrombocytopenia
  • Anti-cardiolipin Ab, lupus anticoagulant, anti-beta2-GPI

Common Manifestations Shared Across CVDs:

  • Constitutional: fever, fatigue, weight loss
  • Arthralgia/arthritis
  • Raynaud's phenomenon
  • Serositis (pleuritis/pericarditis)
  • Interstitial lung disease
  • Pulmonary hypertension
  • Renal involvement
  • Peripheral neuropathy
  • Elevated inflammatory markers (ESR, CRP)
  • Positive ANA

Q10. Clinical Features, Diagnosis and Treatment of Hypothyroidism (10 marks)

Definition

Hypothyroidism is a clinical syndrome resulting from deficiency of thyroid hormones (T3 and T4), leading to slowing of metabolic processes throughout the body.

Classification

Primary Hypothyroidism (>95%): Thyroid gland failure
  • Hashimoto's thyroiditis (most common in iodine-sufficient areas) - autoimmune
  • Iodine deficiency (most common worldwide cause)
  • Post-thyroidectomy, post-radioiodine therapy
  • Drugs: amiodarone, lithium, interferons, checkpoint inhibitors
  • Infiltrative diseases (amyloidosis, sarcoidosis)
Secondary: TSH deficiency (pituitary disease)
Tertiary: TRH deficiency (hypothalamic disease)
Congenital Hypothyroidism: Thyroid dysgenesis/dyshormonogenesis; screening by TSH at birth

Clinical Features

"Everything Slows Down"
SystemFeatures
GeneralFatigue, lethargy, weight gain (despite poor appetite), cold intolerance, hoarseness
SkinDry, coarse, thickened skin; non-pitting edema (myxedema); brittle hair; alopecia; loss of outer 1/3 of eyebrows (Hertoghe's sign); dry/pale/yellowish skin (carotenemia)
CVSBradycardia, diastolic hypertension, pericardial effusion, increased LDL/total cholesterol
GIConstipation, decreased appetite, ileus (severe)
NeuroSlow mentation, poor memory, depression, cerebellar ataxia, carpal tunnel syndrome, delayed relaxation of deep tendon reflexes ("hung-up reflexes")
ReproductiveMenorrhagia, galactorrhea, decreased libido, infertility
MusclesProximal myopathy, elevated CK, myalgia, cramps
FacePeriorbital puffiness, macroglossia, thick lips, expressionless facies
Myxedema Coma (severe/life-threatening):
  • Hypothermia, altered consciousness, hypoventilation, bradycardia, hypotension
  • Precipitants: cold exposure, infection, sedatives, surgery
  • Emergency: IV T3/T4, hydrocortisone, supportive care

Diagnosis

TSH (most sensitive and first-line test):
  • Primary hypothyroidism: TSH ↑ + Free T4 ↓
  • Subclinical hypothyroidism: TSH ↑ + Free T4 normal
  • Secondary/Tertiary: TSH low/normal + Free T4 ↓
Other tests:
  • Anti-TPO antibodies (Hashimoto's - positive in >90%)
  • Anti-thyroglobulin antibodies
  • Lipid profile: elevated LDL, total cholesterol
  • FBC: normocytic anemia (or macrocytic if pernicious anemia coexists)
  • Serum sodium: may be low (SIADH)
  • ECG: bradycardia, low voltage, flat/inverted T waves
  • Ultrasound thyroid: heterogeneous echogenicity in Hashimoto's

Treatment

Levothyroxine (L-T4) - standard treatment:
  • Starting dose: 1.6 mcg/kg/day in young healthy adults
  • Start low (25-50 mcg/day) in elderly or cardiac patients
  • Taken on empty stomach, 30-60 minutes before breakfast
  • Avoid taking with calcium, iron supplements (interfere with absorption)
  • Titrate every 6-8 weeks based on TSH
  • Target TSH: 0.5-2.5 mU/L (lower target in young; 1-4 mU/L acceptable in elderly)
  • Continue lifelong (for Hashimoto's/post-ablation)
Myxedema Coma: IV liothyronine (T3) ± levothyroxine + IV hydrocortisone (adrenal insufficiency may coexist) + supportive care (warming, ventilation)
Subclinical hypothyroidism: Treat if TSH >10 mU/L, or if symptomatic, or if pregnant/planning pregnancy, or if positive anti-TPO antibodies
These answers are based on Harrison's Principles of Internal Medicine (22e), Goldman-Cecil Medicine, and standard MBBS examination requirements. Each answer carries 10 marks and is structured to cover definition, clinical features, diagnosis, and management as asked.
This is a shared conversation. Sign in to Orris to start your own chat.